Effectiveness of Anti-Psychotics and Related Drugs in the Huntington French-Speaking Group Cohort
PLoS ONE. 2014-01-15; 9(1): e85430
DOI: 10.1371/JOURNAL.PONE.0085430
Read on PubMed
1. PLoS One. 2014 Jan 15;9(1):e85430. doi: 10.1371/journal.pone.0085430. eCollection
2014.
Effectiveness of anti-psychotics and related drugs in the Huntington
French-speaking group cohort.
Désaméricq G(1), Dolbeau G(2), Verny C(3), Charles P(4), Durr A(5), Youssov K(6),
Simonin C(7), Azulay JP(8), Tranchant C(9), Goizet C(10), Damier P(11),
Broussolle E(12), Demonet JF(13), Morgado G(14), Cleret de Langavant L(6),
Macquin-Mavier I(15), Bachoud-Lévi AC(6), Maison P(6).
Author information:
(1)Equipe 01, U955, Inserm, Créteil, France ; Faculté de médecine, Université
Paris Est, Créteil, France ; Service de Pharmacologie Clinique, Hôpital H. Mondor
– A. Chenevier, AP-HP, Créteil, France ; Département d’Etudes Cognitives, Ecole
Normale Supérieure, Paris, France.
(2)Equipe 01, U955, Inserm, Créteil, France ; Faculté de médecine, Université
Paris Est, Créteil, France ; Unité de recherche clinique, Hôpital H. Mondor – A.
Chenevier, AP-HP, Créteil, France.
(3)Centre de référence des maladies neurogénétiques, service de neurologie, CHU
d’Angers, Angers, France ; UMR CNRS 6214 – INSERM U1083, Angers, France.
(4)Centre de référence Maladie de Huntington, Hôpital H. Mondor – A. Chenevier,
AP-HP, Créteil, France ; Département de génétique, Hôpital de la salpêtrière,
AP-HP, Paris, France.
(5)Centre de référence Maladie de Huntington, Hôpital H. Mondor – A. Chenevier,
AP-HP, Créteil, France.
(6)Equipe 01, U955, Inserm, Créteil, France ; Faculté de médecine, Université
Paris Est, Créteil, France ; Département d’Etudes Cognitives, Ecole Normale
Supérieure, Paris, France ; Centre de référence Maladie de Huntington, Hôpital H.
Mondor – A. Chenevier, AP-HP, Créteil, France.
(7)Departement of Neurology and Movement Disorders, CHRU Lille, Lille, France ;
UMR837 INSERM – JPArc Team 6, Lille, France ; University Lille 2/Law & Health,
Lille, France.
(8)Service de Neurologie et pathologie du mouvement, Hôpital de la Timone,
Marseille, France.
(9)Service de Neurologie, CHU Hautepierre, Strasbourg, France ; Université de
Strasbourg, Strasbourg, France.
(10)Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et
Métabolisme (MRGM), EA4576, CHU Bordeaux, Service de Génétique médicale,
Bordeaux, France.
(11)Centre d’Investigation Clinique 004, Inserm, Nantes, France.
(12)Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Université
Lyon I, Lyon, France ; Service de Neurologie C, Hôpital Neurologique Pierre
Wertheimer, Hospices Civils de Lyon, Lyon, France ; Centre de Neurosciences
Cognitives, UMR5229, CNRS, Bron, France.
(13)Centre Leenaards de la Mémoire, Département des Neurosciences Cliniques,
CHUV, Lausanne, Switzerland.
(14)Faculté de médecine, Université Paris Est, Créteil, France ; Centre
d’Investigation Clinique 006, Inserm, Créteil, France ; Pôle Recherche clinique
Santé Publique, Hôpital H. Mondor – A. Chenevier, AP-HP, Créteil, France.
(15)Faculté de médecine, Université Paris Est, Créteil, France ; Service de
Pharmacologie Clinique, Hôpital H. Mondor – A. Chenevier, AP-HP, Créteil, France.
PURPOSE: Huntington’s disease is a rare condition. Patients are commonly treated
with antipsychotics and tetrabenazine. The evidence of their effect on disease
progression is limited and no comparative study between these drugs has been
conducted. We therefore compared the effectiveness of antipsychotics on disease
progression.
METHODS: 956 patients from the Huntington French Speaking Group were followed for
up to 8 years between 2002 and 2010. The effectiveness of treatments was assessed
using Unified Huntington’s Disease Rating Scale (UHDRS) scores and then compared
using a mixed model adjusted on a multiple propensity score.
RESULTS: 63% of patients were treated with antipsychotics during the survey
period. The most commonly prescribed medications were dibenzodiazepines (38%),
risperidone (13%), tetrabenazine (12%) and benzamides (12%). There was no
difference between treatments on the motor and behavioural declines observed,
after taking the patient profiles at the start of the drug prescription into
account. In contrast, the functional decline was lower in the dibenzodiazepine
group than the other antipsychotic groups (Total Functional Capacity: 0.41 ± 0.17
units per year vs. risperidone and 0.54 ± 0.19 vs. tetrabenazine, both p